for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG

NOVN.S

Latest Trade

81.06CHF

Change

-0.20(-0.25%)

Volume

4,712,696

Today's Range

80.46

 - 

81.60

52 Week Range

65.09

 - 

96.38

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
81.26
Open
81.24
Volume
4,712,696
3M AVG Volume
131.12
Today's High
81.60
Today's Low
80.46
52 Week High
96.38
52 Week Low
65.09
Shares Out (MIL)
2,274.51
Market Cap (MIL)
199,980.00
Forward P/E
15.45
Dividend (Yield %)
3.64

Next Event

Novartis AG at Societe Generale Premium Review Conference

Latest Developments

More

Molecular Partners Doses First Cohort In Phase 1 Trial Of Mp0420

Mesoblast Posts Qtrly Loss Attributable At US$24.5 Million

Novartis Secures Exclusive Rights For Potential Acute Respiratory Distress Syndrome Cell Therapy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

4056

Switzerland

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Alex Krauer

Honorary Chairman of the Board

Daniel L. Vasella

Honorary Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Key Stats

2.10 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

49.1K

2018

51.9K

2019

47.4K

2020(E)

49.6K
EPS (USD)

2017

4.860

2018

5.150

2019

5.400

2020(E)

5.796
Price To Earnings (TTM)
28.97
Price To Sales (TTM)
4.45
Price To Book (MRQ)
3.73
Price To Cash Flow (TTM)
16.95
Total Debt To Equity (MRQ)
70.07
LT Debt To Equity (MRQ)
51.72
Return on Investment (TTM)
7.66
Return on Equity (TTM)
5.78

Latest News

Latest News

Novartis starts share buyback, highlights product pipeline

Novartis is initiating a previously announced share buyback worth up to $2.5 billion, it said https://www.novartis.com/news/media-releases/novartis-highlights-confidence-growing-sales-margin-expansion-fueled-market-brands-and-rich-pipeline-annual-meet-management-investor-event...

Novartis starts share buyback, highlights product pipeline

Novartis is initiating a previously announced share buyback worth up to $2.5 billion, it said on Tuesday as it highlighted its research and development pipeline in an investor presentation.

Novartis signs $50 million deal for Mesoblast cell therapy for COVID, beyond

Novartis <NOVN.S> aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast <MSB.AX> that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.

Novartis identifies possible risk factors for Beovu patients

Patients who had certain eye problems before they were treated with Novartis's Beovu had a higher risk of suffering from vision-threatening conditions after treatment, the Swiss drugmaker said on Saturday, based on a safety review.

Novartis arthritis drug fails to help COVID-19 patients

Novartis's <NOVN.S> canakinumab failed to help COVID-19 patients survive without invasive ventilation compared with standard therapy, the Swiss drugmaker said on Friday, dashing hopes the arthritis drug could be repurposed during the pandemic.

Novartis buys Vedere Bio, whose founders helped blind mice see

Swiss drugmaker Novartis is buying Vedere Bio, hoping gene therapy technology that has helped blind mice to see will produce similar results in people with inherited conditions that cause them to lose their sight.

Molecular Partners jumps after Novartis deal for potential COVID-19 drugs

Molecular Partners' <MOLN.S> shares jumped as much as a third on Wednesday after Swiss drugs giant Novartis <NOVN.S> inked a deal to license two of the Zurich-based biotech company's antiviral drugs that it hopes to use to treat COVID-19 patients.

Novartis upbeat as drugmakers see hospitals coping with COVID

Novartis joined rivals Merck, Johnson & Johnson and Roche in predicting the worst of the pandemic may be over for drugmakers, amid signs healthcare systems have learned how to cope with surging infections without shutting down all services.

Novartis CEO says 2020 guidance could be affected if COVID-19 lockdowns resume

Novartis <NOVN.S> Chief Executive Vas Narasimhan said on Tuesday that he expects volatility in health care systems due to rising COVID-19 infections, but added hospitals are getting better at dealing with the pandemic, compared with earlier in the year.

Novartis to pursue SMA drug branaplam in Huntington's disease

Novartis is seeking to repurpose its investigational oral spinal muscular atrophy (SMA) drug branaplam to treat Huntington's disease, the Swiss drugmaker said on Wednesday, as it plans a clinical trial after winning U.S. orphan drug designation.

Novartis sees EU OK ahead after panel nod for $10 bln anti-cholesterol prospect

Swiss drugmaker Novartis grabbed a key European panel's recommendation for its prospective cholesterol drug Leqvio on Friday, clearing the way for its approval in the next couple of months.

Novartis faces delay after FDA asks for another Zolgensma study

Novartis's bid to expand its $2.1 million-per-patient gene therapy Zolgensma to more spinal muscular atrophy patients faces a possible delay after U.S. regulators requested another study in older children getting the drug via a spinal infusion.

BioNTech buys German site from Novartis to boost vaccine output

BioNTech is buying a production site for the COVID-19 vaccine it is developing with Pfizer, aiming to boost output by several hundred million doses next year, and hopes to have the shot ready to file for approval in October.

Novartis ties bond sale to malaria treatment access in sustainability push

Novartis raised 1.85 billion euros on Wednesday from the sale of a bond on which interest payments will rise if the drugmaker fails to expand access to medicines and programmes to combat malaria and leprosy in a number of developing countries.

Roche says two-thirds of Evrysdi patients had got rival treatments

Swiss drugmaker Roche on Monday said two-thirds of spinal muscular atrophy (SMA) patients now taking its newly approved drug Evrysdi have previously received rival treatments Zolgensma from Novartis or Biogen's Spinraza.

Novartis aims to expand Beovu use after safety fears hurt launch

Novartis's Beovu matched Regeneron's Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said on Monday, after early safety stumbles for the medicine in another condition caused disappointing early sales.

Novartis says Beovu matched rival Eylea in visual acuity in eye disease

Novartis on Monday said its eye drug Beovu matched rival Eylea from Regeneron in visual acuity at one year in patients with diabetic macular edema (DME), as the Swiss drugmaker seeks to regain momentum with the drug after early safety stumbles.

France fines Roche, Novartis 444 million euros in ongoing eye drug clash

Switzerland's Novartis and Roche were fined 444 million euros (403.55 million pounds)by France, after its competition authority said on Wednesday they used abusive practices to push costly eye injection Lucentis over a cheaper drug.

Roche studies Ocrevus, experimental drug in bid to defend MS franchise

Roche aims to defend its multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of its $4 billion-per-year Ocrevus product and advanced trials of an experimental medicine, fenebrutinib.

Novartis sets out new sustainability targets on patient outreach, carbon neutrality

Drugmaker Novartis on Tuesday announced new sustainability targets, including boosting access to its medicines and global outreach as well as aiming to make its supply chain carbon neutral by 2030.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up